Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis

NCT03315130 is registered in ClinicalTrials.gov with Ra Pharmaceuticals as lead sponsor.

NCT NCT03315130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03315130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis
Lead sponsor
Ra Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
October 11, 2017
Completion date
November 19, 2020
Enrollment
45 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis